Project Title: “Exploitation of extracellular vesicles for precision diagnostics of prostate cancer”
Funding: ERA-NET TRANSCAN-2 Joint Transnational Call for Proposals 2016 (JTC 2016) project application “Exploitation of extracellular vesicles for precision diagnostics of prostate cancer”
Project No.: PROSCANEXO ES RTD/2017/28 –PRL/17/10
Period: 36 months (01.01.2018.-31.12.2020.)
Coordinator: Prof. Jesús Martinez de la Fuente (Spain) CIBER
Partners: Consorcio Centro de Investigación Biomédica en Red, M.P., Erasmus Medical Center, Oslo University Hospital, The Norwegian Radium Hospital, Latvian Biomedical Research and Study Centre, University of Tartu
BMC Principle Investigator: Dr. Biol. Aija Linē
The overall aim of PROSCANEXO is to establish technically and clinically validated non- invasive tool for PCa diagnosis ang prognosis based on the analysis of EV counts and molecular cargo in patients` biofluids.
BMC main task in this project is EVs isolation from biofluids using ultracentrifugation, SEC and/or immune-isolation. Testing of RNA biomarkers by qRT_PCR in a test set of PCa patients and controls. Establishing ddPCR-based assays for the absolute quantification of the most relevent RNA biomarkers. Primary validation of the RNA markers and assay conditions to select the final parameters for validation in Project WP4.
Information published 02.01.2018.